Dr Reddys Laboratories Stock Last Dividend Paid
RDY Stock | USD 75.21 0.43 0.58% |
Dr Reddys Laboratories fundamentals help investors to digest information that contributes to Dr Reddys' financial success or failures. It also enables traders to predict the movement of RDY Stock. The fundamental analysis module provides a way to measure Dr Reddys' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dr Reddys stock.
RDY | Last Dividend Paid |
Dr Reddys Laboratories Company Last Dividend Paid Analysis
Dr Reddys' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Current Dr Reddys Last Dividend Paid | 40.0 |
Most of Dr Reddys' fundamental indicators, such as Last Dividend Paid, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dr Reddys Laboratories is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
RDY Last Dividend Paid Driver Correlations
Understanding the fundamental principles of building solid financial models for Dr Reddys is extremely important. It helps to project a fair market value of RDY Stock properly, considering its historical fundamentals such as Last Dividend Paid. Since Dr Reddys' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Dr Reddys' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Dr Reddys' interrelated accounts and indicators.
Click cells to compare fundamentals
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
Competition |
Based on the recorded statements, Dr Reddys Laboratories has a Last Dividend Paid of 40.0. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The last dividend paid for all United States stocks is notably lower than that of the firm.
Dr Reddys Current Valuation Drivers
We derive many important indicators used in calculating different scores of Dr Reddys from analyzing Dr Reddys' financial statements. These drivers represent accounts that assess Dr Reddys' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Dr Reddys' important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Market Cap | 511.9B | 746.6B | 702.3B | 776.0B | 698.4B | 733.4B | |
Enterprise Value | 531.9B | 762.0B | 721.2B | 783.7B | 705.4B | 740.6B |
RDY Fundamentals
Return On Equity | 0.21 | ||||
Return On Asset | 0.12 | ||||
Profit Margin | 0.19 % | ||||
Operating Margin | 0.25 % | ||||
Current Valuation | (40.18 B) | ||||
Shares Outstanding | 166.53 M | ||||
Shares Owned By Institutions | 15.17 % | ||||
Number Of Shares Shorted | 751 K | ||||
Price To Earning | 31.58 X | ||||
Price To Book | 3.70 X | ||||
Price To Sales | 0.04 X | ||||
Revenue | 245.88 B | ||||
Gross Profit | 113.84 B | ||||
EBITDA | 108.78 B | ||||
Net Income | 60.48 B | ||||
Cash And Equivalents | 2.93 B | ||||
Cash Per Share | 208.58 X | ||||
Total Debt | 13.47 B | ||||
Debt To Equity | 0.12 % | ||||
Current Ratio | 1.98 X | ||||
Book Value Per Share | 1,609 X | ||||
Cash Flow From Operations | 58.87 B | ||||
Short Ratio | 3.51 X | ||||
Earnings Per Share | 3.75 X | ||||
Price To Earnings To Growth | 4.71 X | ||||
Target Price | 79.86 | ||||
Number Of Employees | 25.86 K | ||||
Beta | 0.34 | ||||
Market Capitalization | 12.68 B | ||||
Total Asset | 322.85 B | ||||
Retained Earnings | 215.59 B | ||||
Working Capital | 118.53 B | ||||
Current Asset | 1.81 B | ||||
Current Liabilities | 976 M | ||||
Annual Yield | 0.01 % | ||||
Five Year Return | 0.72 % | ||||
Net Asset | 322.85 B | ||||
Last Dividend Paid | 40.0 |
About Dr Reddys Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dr Reddys Laboratories's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dr Reddys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dr Reddys Laboratories based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Dr Reddys Laboratories offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dr Reddys' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dr Reddys Laboratories Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dr Reddys Laboratories Stock:Check out Dr Reddys Piotroski F Score and Dr Reddys Altman Z Score analysis. Note that the Dr Reddys Laboratories information on this page should be used as a complementary analysis to other Dr Reddys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for RDY Stock analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Dr Reddys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dr Reddys. If investors know RDY will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dr Reddys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.103 | Dividend Share 40 | Earnings Share 3.75 | Revenue Per Share 272.4618 | Quarterly Revenue Growth 0.066 |
The market value of Dr Reddys Laboratories is measured differently than its book value, which is the value of RDY that is recorded on the company's balance sheet. Investors also form their own opinion of Dr Reddys' value that differs from its market value or its book value, called intrinsic value, which is Dr Reddys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dr Reddys' market value can be influenced by many factors that don't directly affect Dr Reddys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dr Reddys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dr Reddys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dr Reddys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.